The Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 Experts

7d ago, source:

Analysts have recently evaluated Ocular Therapeutix and provided 12-month price targets. The average target is $17.5, ...

Optimistic Buy Rating for Ocular Therapeutix Amid Early-Stage NPDR Study and Wet AMD Potential

1d ago, source:

Analyst Colleen M. Kusy of Robert W. Baird reiterated a Buy rating on Ocular Therapeutix (OCUL – Research Report), retaining the price ...

Ocular Therapeutix announces positive topline Phase 1 data for Axpaxli in diabetic retinopathy

4d ago, source: ophthalmologytimes

According to the company, 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity ...

Ocular Therapeutix Inc OCUL

4d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

7d ago, source:

Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea ...

Ocular marks early-stage trial win for diabetic retinopathy candidate

on MSN ago, source:

Ocular Therapeutix (OCUL stock gained on positive Phase 1 results for its retinal disease candidate Axpaxli in diabetic ...

Ocular Therapeutix CEO Mattessich To Step Down, Dugel To Succeed

8d ago, source: Nasdaq

(RTTNews) - Ocular Therapeutix, Inc. (OCUL) announced on Monday that President and CEO Antony Mattessich will be stepping down. Mattessich is being succeeded by Pravin Dugel, executive chairman ...

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

5d ago, source:

Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm No patients in ...

Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

7d ago, source: Nasdaq

“I am honored to be part of the Ocular Therapeutix team. My experience as a retinal surgeon, combined with my background in scientific and clinical research and direct patient care inspired my ...

Ocular Therapeutix(TM) Strengthens Clinical Team with Appointment of Key Retinal Leaders

7d ago, source:

Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata Saroj ...

Ocular Therapeutix, Inc.: Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic Retinopathy

5d ago, source:

Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm No patients in the AXPAXLI ...